A Revolutionary Targeted Therapy for Hematological Malignancies

　　Ibrutinib(brand name Imbruvica),developed by Janssen Pharmaceuticals,is a groundbreaking small molecule targeted therapy.By selectively inhibiting Bruton’s tyrosine kinase(BTK),it disrupts the B-cell receptor signaling pathway,suppressing malignant B-cell proliferation.Proven effective in various hematological malignancies,Ibrutinib offers transformative treatment options.

　　Indications：

　　1.Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL):

　　○Approved for adult patients,including treatment-naïve and relapsed/refractory cases,particularly those with high-risk 17p deletion.

　　○Monotherapy or combination with rituximab significantly prolongs progression-free survival(PFS).

　　2.Waldenström’s Macroglobulinemia(WM):

　　○First-line or later-line treatment,used alone or with rituximab to rapidly reduce IgM levels and alleviate symptoms.

　　3.Chronic Graft-Versus-Host Disease(cGVHD):

　　○Second-line therapy for children≥1 year and adults who fail steroid treatment,improving fibrotic lesions in skin,mouth,and other organs.

　　Adverse Reactions：

　　●Common in B-cell malignancies(≥30%):Thrombocytopenia,diarrhea,fatigue,musculoskeletal pain,neutropenia,rash,anemia,bruising,nausea.

　　●Common in cGVHD patients(≥20%):Fatigue,anemia,bruising,diarrhea,thrombocytopenia,musculoskeletal pain,fever,muscle spasms,stomatitis,bleeding,nausea,abdominal pain,pneumonia,headache.

　　Precautions：

　　1.Bleeding Risk:Monitor for bleeding events and manage as needed.

　　2.Infection Surveillance:Assess for fever or infections promptly.

　　3.Cardiovascular Risks:Monitor for arrhythmias and heart failure;report cardiac symptoms.

　　4.Liver Function Monitoring:Regularly test hepatic enzymes to prevent drug-induced injury.

　　5.Tumor Lysis Syndrome(TLS):Risk-stratify and prophylactically manage TLS.

　　6.Embryo-Fetal Toxicity:Contraindicated during pregnancy;advise contraception for patients of reproductive potential.

　　7.Drug Interactions:

　　○Avoid strong CYP3A inhibitors(e.g.,itraconazole);reduce dose to 140mg/day if unavoidable.

　　○Temporarily suspend Ibrutinib during short-term(≤7 days)anti-infective use.

　　○Avoid CYP3A inducers(e.g.,rifampin).

　　Medication Tips：

　　●Avoid grapefruit and Seville oranges(inhibit CYP3A,elevating drug levels).

　　●Schedule monthly blood counts,liver function tests,and periodic cardiac assessments.